. 2006 Mar 14;103(12):4610–4615. doi: 10.1073/pnas.0511348103

Table 6.

Effects of GHRH antagonists MZ-J-7-114 and JV-1-38 on the growth of human PC-3 androgen-independent prostate cancer in nude mice and serum IGF-levels

Treatment	Tumor volume, mm³		Tumor volume doubling time, days	Tumor weight, mg (% inhibition)	Serum IGF-I, ng/ml (% inhibition)
Treatment	Initial	Final (% inhibition)	Tumor volume doubling time, days	Tumor weight, mg (% inhibition)	Serum IGF-I, ng/ml (% inhibition)
Control	28.4 ± 4.2	351.1 ± 84.9	8.3 ± 0.7	282.7 ± 72.1	262 ± 18.1
JV-1-38^* (10 μg/day)	29.3 ± 3.8	351.0 ± 72.9	8.7 ± 0.7	254.3 ± 52.0 (10)	293 ± 28.0
MZ-J-7-114 (5 μg/day)	26.5 ± 3.7	199.3 ± 40.4 (43)^†^‡	12.6 ± 2.5^†	119.1 ± 25.3 (58)^†^‡	175 ± 12.9 (33%)^¶

*Reference compound;

†, P < 0.05 vs. control;

‡, P < 0.05 vs. JV-1-38;

¶, P < 0.001 vs. control and JV-1-38.